CRP and hyperlipidemia: The sHT cohort with high fibrinogen levels showed a higher prevalence of hyperlipidemia, platelets, white blood cell (WBC), C-reaction protein (CRP), and a lower usage rate of antiplatelet drugs compared to the subjects with low fibrinogen levels.